Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study - Concepedia

Concepedia

Publication | Open Access

Long-Term Survival Advantage and Prognostic Factors Associated With Intraperitoneal Chemotherapy Treatment in Advanced Ovarian Cancer: A Gynecologic Oncology Group Study

DOI Full Paper Access

282

Citations

35

References

2015

Year

Devansu Tewari, James Java, Ritu Salani, Deborah K. Armstrong, Maurie Markman, Thomas J. Herzog, Bradley J. Monk, John K. Chan

Journal of Clinical Oncology

Abstract

The advantage of IP over intravenous chemotherapy extends beyond 10 years. IP therapy enhanced survival of those with gross residual disease. Survival improved with increasing number of IP cycles.

References

	Year	Citations

Page 1